Pharmaceutical

STAT+: Pharmalittle: Wegovy cuts heart attack risk in m...

Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a la...

NYU researchers tackle the challenge of making MRI mach...

MRI machines typically cost between $1 million and $3 million. NYU radiologists ...

Opinion: Congress must reauthorize the National Advisor...

Congress must reauthorize the National Advisory Committee for Seniors and Disast...

STAT+: Eli Lilly’s chief scientist on new obesity drug ...

An interview with Eli Lilly’s chief scientist featured a discussion of new obesi...

The U.K. just cleared a drug to prevent breast cancer. ...

Doctors in the U.S. have long prescribed preventive drugs for people at risk of ...

STAT+: Novo Nordisk wants to be a cardiovascular compan...

“We have a clear vision of being an established cardiovascular company, just as ...

STAT+: Patients loved Carbon Health’s diabetes program....

Patients loved Carbon Health's telehealth-based program for managing diabetes. T...

STAT+: In first test for base editing, Verve’s one-time...

Verve Therapeutics said that the first 10 people to receive a one-time treatment...

STAT+: Anthos stroke drug appears safer than common blo...

An investigational drug aimed at preventing strokes significantly reduced the ri...

Bristol Myers Squibb’s CAR-T Breyanzi wins FDA priority...

The US Food and Drug Administration (FDA) has granted priority review for B...

BIO-Europe 2023: Barriers remain in the AI pharma revol...

Despite the shift towards artificial intelligence (AI) in drug discovery and de...

Novartis’ urticaria drug meets all endpoints in Phase I...

Novartis’ remibrutinib met all the primary and secondary endpoints at 12 weeks ...

AstraZeneca posts 16% drop in Q3 2023 profit after tax

AstraZeneca has posted a profit after tax of $1.37bn for the third quarter (Q3)...

Bayer and Recursion expand oncology research partnership

Bayer has expanded a drug discovery research partnership with Recursion Pharmac...

EC approves Daiichi Sankyo’s Vanflyta for acute myeloid...

The European Commission (EC) has granted approval for Daiichi Sankyo’s Vanflyta...

FDA approves Takeda’s Adzynma for rare blood clotting d...

The US Food and Drug Administration (FDA) has granted approval for Takeda’s Adz...